Literature DB >> 16055568

Ovarian conservation at the time of hysterectomy for benign disease.

William H Parker1, Michael S Broder, Zhimei Liu, Donna Shoupe, Cindy Farquhar, Jonathan S Berek.   

Abstract

OBJECTIVE: Prophylactic oophorectomy is often recommended concurrent with hysterectomy for benign disease. The optimal age for this recommendation in women at average risk for ovarian cancer has not been determined.
METHODS: Using published age-specific data for absolute and relative risk, both with and without oophorectomy, for ovarian cancer, coronary heart disease, hip fracture, breast cancer, and stroke, a Markov decision analysis model was used to estimate the optimal strategy for maximizing survival for women at average risk of ovarian cancer. For each 5-year age group from 40 to 80 years, 4 strategies were compared: ovarian conservation or oophorectomy, and use of estrogen therapy or nonuse. Outcomes, as proportion of women alive at age 80 years, were measured. Sensitivity analyses were performed, varying both relative and absolute risk estimates across the range of reported values.
RESULTS: Ovarian conservation until age 65 benefits long-term survival for women undergoing hysterectomy for benign disease. Women with oophorectomy before age 55 have 8.58% excess mortality by age 80, and those with oophorectomy before age 59 have 3.92% excess mortality. There is sustained, but decreasing, benefit until the age of 75, when excess mortality for oophorectomy is less than 1%. These results were unchanged following multiple sensitivity analyses and were most sensitive to the risk of coronary heart disease.
CONCLUSION: Ovarian conservation until at least age 65 benefits long-term survival for women at average risk of ovarian cancer when undergoing hysterectomy for benign disease.

Entities:  

Mesh:

Year:  2005        PMID: 16055568     DOI: 10.1097/01.AOG.0000167394.38215.56

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  48 in total

Review 1.  Hysterectomy for heavy menstrual bleeding.

Authors:  Eva van der Meij; Mark Hans Emanuel
Journal:  Womens Health (Lond)       Date:  2016-01-12

2.  Age alters cerebrovascular inflammation and effects of estrogen.

Authors:  Lorraine Sunday; Christa Osuna; Diana N Krause; Sue P Duckles
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-01-05       Impact factor: 4.733

3.  Reassessing hysterectomy.

Authors:  Elizabeth A Stewart; Lynne T Shuster; Walter A Rocca
Journal:  Minn Med       Date:  2012-03

Review 4.  Progesterone and human cognition.

Authors:  V W Henderson
Journal:  Climacteric       Date:  2018-06-01       Impact factor: 3.005

5.  Influence of hysterectomy on long-term fracture risk.

Authors:  L Joseph Melton; Sara J Achenbach; John B Gebhart; Ebenezer O Babalola; Elizabeth J Atkinson; Adil E Bharucha
Journal:  Fertil Steril       Date:  2007-01-30       Impact factor: 7.329

6.  Ovary-sparing hysterectomy: is it right for your patient?

Authors:  Umang Sharma; Sarah-Anne Schumann
Journal:  J Fam Pract       Date:  2009-09       Impact factor: 0.493

7.  Evidence-based medicine: an analysis of prophylactic bilateral oophorectomy at time of hysterectomy for benign conditions.

Authors:  C A Larson
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

8.  Opportunistic salpingectomy during vaginal hysterectomy for a benign pathological condition.

Authors:  Gery Lamblin; Capucine Meysonnier; Stéphanie Moret; Béatrice Nadaud; Georges Mellier; Gautier Chene
Journal:  Int Urogynecol J       Date:  2017-07-13       Impact factor: 2.894

Review 9.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

10.  Mitochondrial effects of estrogen are mediated by estrogen receptor alpha in brain endothelial cells.

Authors:  Ali Razmara; Lorraine Sunday; Chris Stirone; Xiao Bo Wang; Diana N Krause; Sue P Duckles; Vincent Procaccio
Journal:  J Pharmacol Exp Ther       Date:  2008-03-19       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.